NY-SLICE/SOMPO
16.1.2020 15:17:05 CET | Business Wire | Press release
Slice Labs Inc. (Slice) , the first on-demand insurance platform and Sompo Holdings (Asia) Pte. Ltd. (SOMPO) – part of top international insurer Sompo Holdings, have released an enhanced version of the travel insurance product, TravelJoy, in Thailand using social distribution through LINE LIFF Platform making on-demand trip protection services available to 44 million LINE users in the country.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200116005045/en/
“SOMPO’s partnership with Slice and relationship with LINE blend a common commitment to introduce more convenient and user-friendly digital services that best aid Thailand’s increasingly cashless society,” commented Patrick Chin, Head of Digital and Branding, Asia Pacific at SOMPO. “We believe in meeting customers where they are at with innovative technologies that support their lifestyles. Slice ICS is an incredible asset that has positioned SOMPO to develop and implement a progressive product solution within a short timeframe.”
Sompo Insurance Thailand (Sompo Thailand) CEO, Chayanna Siripirom echoed, “More than 90% of Thailand’s mobile internet users are using LINE commercially and socially. Now that TravelJoy is made available on our very own LINE OA, we can offer better services and solutions to our customers, as well as reach out to a larger market.”
The joint travel insurance product, TravelJoy, will include life and medical, flight delay/cancellation, and baggage/belongings coverage. As part of the offering, Slice ICS will integrate with pan-Asian payments provider, 2C2P, that serves 620 million banked and unbanked Southeast Asia customers. Available in English and Thai, the Slice and SOMPO TravelJoy is purchased via Sompo Thailand LINE Official Account on the LINE platform in under three minutes and costs ₿500 (Thai baht) (USD16) per average customer.
“This is the type of ecosystem example where advanced financial services, payments, and insurance products are setting a global example for how to reinvent customer experiences,” said Tim Attia, CEO of Slice Labs. “Asia is known for pushing the envelope much earlier in adopting new technologies compared to other countries around the world. This makes our vision for ecosystems powered by on-demand insurance a great option for the region and not a customer experience that is decades in the future.”
About Sompo Holdings (Asia):
Based in Singapore, Sompo Holdings (Asia) Pte. Ltd. is the holding company for its Asia Pacific entities, except Japan and is part of Sompo Holdings headquartered in Tokyo, Japan. With more than 70 years of trusted presence in Asia , our business spreads across 14 markets with over 4,000 employees in the region. We are now the Top 10 Largest Non-Life Insurance Companies in Indonesia and Malaysia, and we have forged strategic partnerships to access a wider network of resources and distribution.
Learn more about SOMPO by visiting www.sompo-asia.com .
About Slice:
Slice Labs Inc. is the insurance engine behind tomorrow’s cloud-based, on-demand digital services ecosystems for the new economy. Through the Slice Labs Insurance Cloud Services (ICS) platform, Slice Labs is enabling insurers, technology companies, and other service providers to build truly intelligent and intuitive, pay-as-you-go digital insurance products protecting the insured anytime and anywhere. To stay up to date with Slice, visit https://www.slice.is and follow @SliceLabs on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom